Current management and future challenges in salivary glands cancer

Abstract

Salivary gland cancers (SGCs) are rare, accounting for less than 5% of all malignancies of the head and neck region, and are morphologically heterogeneous. The diagnosis is mainly based on histology, with the complementary aid of molecular profiling, which is helpful in recognizing some poorly differentiated, borderline, or atypical lesions. Instrumental imaging defines the diagnosis, representing a remarkable tool in the treatment plan. Ultrasound and magnetic resonance are the most common procedures used to describe the primary tumour. The treatment of SGCs is multimodal and consists of surgery, radiotherapy, and systemic therapy; each treatment plan is, however, featured on the patient and disease’s characteristics. On 24 June 2022, in the meeting “Current management and future challenges in salivary gland cancers” many experts in this field discussed the state of the art of SGCs research, the future challenges and developments. After the meeting, the same pool of experts maintained close contact to keep these data further updated in the conference proceedings presented here. This review collects the insights and suggestions that emerged from the discussion during and after the meeting per se.

Advances in H2O2-supplying materials for tumor therapy: synthesis, classification, mechanisms, and applications

“…The malignant epithelial tumors mainly include squamous carcinoma, 186 adenocarcinoma, 187 basal cell carcinoma, 188 and etc . These types of tumors usually invade and infiltrate the surrounding tissues such as nerves, 189 vessels, 190,191 and lymphatic nodes. 192 Based on these views, the main treatment for epithelial-derived tumors was intraoperative extended resection.…”

Role of Tumor-Infiltrating Lymphocytes and the Tumor Microenvironment in the Survival of Malignant Parotid Gland Tumors: A Two-Centre Retrospective Analysis of 107 Patients

“…Malignant salivary gland cancers (SGCs) are rare tumors, representing only 3% of all head and neck cancers; in most cases, they are benign (80%) epithelial tumors arising from the parotid gland [ 1 , 2 ]. In the context of parotid tumors, mucoepidermoid carcinoma is the most common, followed by adenoid cystic carcinoma and acinic cell carcinoma [ 2 ]. These tumors present a wide and complex range of biological behaviors and are morphologically heterogeneous, making histopathological diagnosis challenging [ 3 ].…”

“…The World Health Organization (WHO) has recently updated the classification of SGCs by introducing molecular data to define new entities [ 4 ]; however, molecular typing in this field is still in progress [ 5 ]. Currently, most tumors are defined on the basis of histological and immunohistochemical findings, and molecular characterization is not mandatory for diagnosis [ 2 , 5 ].…”

“…Malignant salivary gland cancers (SGCs) are rare tumors, representing only 3% of all head and neck cancers; in most cases, they are benign (80%) epithelial tumors arising from the parotid gland [1,2]. In the context of parotid tumors, mucoepidermoid carcinoma is the most common, followed by adenoid cystic carcinoma and acinic cell carcinoma [2].…”